Source: Molecular Templates, Inc.
Molecular Templates to Present at the Oppenheimer New York Oncology Insight Summit and the UBS Global Healthcare Conference
AUSTIN, Texas, May 14, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, announced today that Eric Poma, Ph.D., Chief Executive Officer and Chief Scientific Officer, will present a corporate overview at the Oppenheimer New York Oncology Insight Summit, and the UBS Global Healthcare Conference, both taking place in New York City.
| Oppenheimer New York Oncology Insight Summit | |
| Date: | Thursday, May 16 |
| Format: | One-on-One Meetings |
| UBS Global Healthcare Conference | |
| Date: | Monday, May 20 |
| Time: | 8:00am Eastern Time |
| Format: | Fireside Chat |
| Webcast: | https://cc.talkpoint.com/ubsx001/052019a_as/?entity=62_RJ1HXDS |
About Molecular Templates
Molecular Templates is a clinical-stage oncology company focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer. We believe our proprietary biologic drug platform technology, referred to as engineered toxin bodies, or ETBs, provides a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics. ETBs utilize a genetically engineered form of Shiga-like Toxin A subunit, or SLTA, a ribosome inactivating bacterial protein, that can be targeted to specifically destroy cancer cells. Additional information about Molecular Templates can be obtained at http://www.mtem.com.
Investor Contact:
Adam Cutler
Chief Financial Officer
adam.cutler@mtem.com
862-204-4006
Source: Molecular Templates, Inc.